1[1] Nagata S,Golstein P.The Fas death factor[J].Science,1995,267:1449～1456．
2[3] Wang DK,Freeman GJ,Levine H,et al.Role of the CD40 and CD 95 (Apo-1/Fas) antigens in the apoptosis of human B-cell malignancies[J].Brit J Haematol,1997,97:409～417．
3[4] Egle A,Villunger A,Marschitz I,et al.Expression of Apo-l/Fas(CD95),Bc12,Bax and Bcl-x in myeloma cell lines:relationship between responsiveness to anti-Fas mab and P53 functional status[J].Brit J Haematol,1997,97:418～428．
5[6] Tamiya S,Etoh K,Suzushima H,et al.Mutation of CD95(Fas/Apo-1) gene in adult T-cell leukemia cells[J].Blood,1998,91:3935～3942．
6[7] Beltinger C,Bohler T,Karawajew L,et al.Mutation analysis of CD95(Apo-1/Fas) in chidhood B-lineage acute lymphoblastic leukemia[J].Brit J Haematol,1998,102:722～728．
7[8] Tsuruda K,Yamada Y,Hirakata Y,et al.Qualitative and quantitative charcterization of Fas (Apo-1/CD95) on leukemia cells derived from patients with B-cell neoplasms[J]. Leuk Res,1999,23:159～166．
8[9] Anthony RS,Mckelvie ND,Graig JI,et al.Fas antigen(CD95)expression in peripheral blood progenitor cells from patients with leukaemia and lymphoma[J].Leuk Lymphome,1998,30:449～458．
9[10] Molica S,Mannella A,Dattilo A,et al.Differential expression of BCL2 oncoprotein and Fas antigen on normal peipheral blood and leukemic bone marrow cells[J].A flow cytometric anaiysis,Haematologica,1996,81:302～309．
10[12] Tomizuka H,Hatake K,Ikeda M,et al． CD95 predicts resonsiveness to tretinoin in acute promyelocytis leukemia[J].Int J Mol Med,1998,1:207～211．
